HENDERSON, NV / ACCESSWIRE / February 5, 2019 / In January, the trend in biotech stocks appeared to be on a positive sloping trajectory as the IBB capped off its strongest month in almost a year. Below are a few biotechnology plays that could be interesting to follow this month.
One we plan to watch is Delcath Systems, Inc. (DCTH). Last September, the stock reached highs above $8 and is now sitting around support at $0.26. With potentially valuable liver cancer treatments in late-stage development (Phase 3 clinical trials) and a new licensing deal with a projected value of up to $45 million, there are factors for potential investors to examine. With not much awareness among investors yet, we think you should start researching DCTH today.
An interventional oncology company focused on treating liver cancers with major upside potential, Delcath Systems, Inc. (DCTH) (Market Cap: $3.051M, Share Price: $0.2733) is an interventional oncology company focused on treating liver cancers. The company has had quite a year. They announced an amendment to their ongoing Phase 3 ocular melanoma metastases clinical trial, raised $7 million via a right offering, increased revenue 20% Y/Y, and had data published in European Radiology among several other milestones.
DCTH made news recently entering a licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension. Medac is a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, Medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.
This comes on the heels of an announcement about the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. This review was conducted on data collected from both the prior randomized protocol and the amended single-arm protocol for the FOCUS Trial. The DSMB again recommended continuation of the study without modification.
With more news on the horizon, there is potential for an event driven breakout. Research DCTH now.
BioTime, Inc. (BTX) (Market Cap: $161.244M, Share Price: $1.27) announced that its affiliate company, OncoCyte Corporation (OCX), a developer of novel, non-invasive tests for the early detection of cancer, has reported positive results from an R&D validation study of DetermaVu™, a non-invasive, liquid biopsy test intended to facilitate clinical decision making in lung cancer diagnosis.
Eyenovia (EYEN) (Market Cap: $45.953M, Share Price: $3.90) reported positive results in a late-stage trial of a device that causes dilation of the eye. The New York-based company said results from the MicroStat Phase 3 MIST-1 study showed a statistically and clinically superior effect using a fixed-combination formulation than either component formulation.
Cara Therapeutics, Inc. (CARA) (Market Cap: $606.297M, Share Price: $15.37) announced completion of enrollment in the KALM-1 Phase 3 trial of KORSUVA™ (CR845/ difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). More than 350 hemodialysis patients with CKD-aP have now been randomized across approximately 60 clinical sites in the United States.
Cronos Group, Inc. (CRON) (Market Cap: $4.111B, Share Price: $23.25) announced in early December 2018 that it had entered into a subscription agreement with Altria Group, Inc., one of the leading tobacco brands in the world, pursuant to which Altria agreed to make an approximately C$2.4 billion equity investment in Cronos Group on a private placement basis in exchange for common shares in the capital of the Company.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communications LLC
View source version on accesswire.com: